Literature DB >> 12368194

Different pattern of allelic loss in Epstein-Barr virus-positive gastric cancer with emphasis on the p53 tumor suppressor pathway.

Bastiaan P van Rees1, Eric Caspers, Axel zur Hausen, Adriaan van den Brule, Paul Drillenburg, Marian A J Weterman, G Johan A Offerhaus.   

Abstract

Both Helicobacter pylori (HP) and Epstein-Barr virus (EBV) have been implicated in carcinogenesis of the stomach. Fifty-seven gastric carcinomas were tested for microsatellite instability and allelic loss at several tumor suppressor loci using 21 polymorphic microsatellite markers. Furthermore, immunohistochemistry for p53 and DPC4/SMAD4 was performed. Results were analyzed according to HP and EBV status of the tumors, as assessed by immunohistochemistry and RNA in situ hybridization, respectively. Fractional allelic loss was lower in EBV-positive carcinomas (n = 15) when compared to EBV-negative carcinomas (P < 0.001). EBV positivity was inversely associated with allelic loss at specific markers on chromosomal arms 5q (APC), 17p (TP53), and 18q (DPC4/SMAD4). Allelic loss at the TP53 locus was not encountered in EBV-positive carcinomas, but occurred in 51% of EBV-negative carcinomas (P < 0.005). Moreover, none of the EBV-positive carcinomas showed unequivocal p53 immunopositivity in contrast to 39% of the EBV-negative carcinomas (P < 0.01). EBV-status was not related to microsatellite instability. There was no correlation between HP-status and any of the molecular alterations tested. In conclusion, EBV-positive gastric carcinomas follow a distinct pathogenesis at the molecular level, in which p53 is not, or differently inactivated.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12368194      PMCID: PMC1867286          DOI: 10.1016/S0002-9440(10)64397-0

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  28 in total

1.  Unique transcription pattern of Epstein-Barr virus (EBV) in EBV-carrying gastric adenocarcinomas: expression of the transforming BARF1 gene.

Authors:  A zur Hausen; A A Brink; M E Craanen; J M Middeldorp; C J Meijer; A J van den Brule
Journal:  Cancer Res       Date:  2000-05-15       Impact factor: 12.701

2.  Epstein-Barr virus-associated gastric carcinomas: relation to H. pylori infection and genetic alterations.

Authors:  M S Wu; C T Shun; C C Wu; T Y Hsu; M T Lin; M C Chang; H P Wang; J T Lin
Journal:  Gastroenterology       Date:  2000-06       Impact factor: 22.682

3.  THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION.

Authors:  P LAUREN
Journal:  Acta Pathol Microbiol Scand       Date:  1965

Review 4.  Molecular epidemiology, pathogenesis and prevention of gastric cancer.

Authors:  C T Stadtländer; J W Waterbor
Journal:  Carcinogenesis       Date:  1999-12       Impact factor: 4.944

5.  Epstein-Barr virus nuclear protein EBNA-3C interacts with the human metastatic suppressor Nm23-H1: a molecular link to cancer metastasis.

Authors:  C Subramanian; M A Cotter; E S Robertson
Journal:  Nat Med       Date:  2001-03       Impact factor: 53.440

6.  Distinct chromosomal aberrations in Epstein-Barr virus-carrying gastric carcinomas tested by comparative genomic hybridization.

Authors:  A zur Hausen; N C van Grieken; G A Meijer; M A Hermsen; E Bloemena; S G Meuwissen; J P Baak; C J Meijer; E J Kuipers; A J van den Brule
Journal:  Gastroenterology       Date:  2001-09       Impact factor: 22.682

7.  The Vienna classification of gastrointestinal epithelial neoplasia.

Authors:  R J Schlemper; R H Riddell; Y Kato; F Borchard; H S Cooper; S M Dawsey; M F Dixon; C M Fenoglio-Preiser; J F Fléjou; K Geboes; T Hattori; T Hirota; M Itabashi; M Iwafuchi; A Iwashita; Y I Kim; T Kirchner; M Klimpfinger; M Koike; G Y Lauwers; K J Lewin; G Oberhuber; F Offner; A B Price; C A Rubio; M Shimizu; T Shimoda; P Sipponen; E Solcia; M Stolte; H Watanabe; H Yamabe
Journal:  Gut       Date:  2000-08       Impact factor: 23.059

8.  Causal relationship between the loss of RUNX3 expression and gastric cancer.

Authors:  Qing Lin Li; Kosei Ito; Chohei Sakakura; Hiroshi Fukamachi; Ken ichi Inoue; Xin Zi Chi; Kwang Youl Lee; Shintaro Nomura; Chang Woo Lee; Sang Bae Han; Hwan Mook Kim; Wun Jae Kim; Hiromitsu Yamamoto; Namiko Yamashita; Takashi Yano; Toshio Ikeda; Shigeyoshi Itohara; Johji Inazawa; Tatsuo Abe; Akeo Hagiwara; Hisakazu Yamagishi; Asako Ooe; Atsushi Kaneda; Takashi Sugimura; Toshikazu Ushijima; Suk Chul Bae; Yoshiaki Ito
Journal:  Cell       Date:  2002-04-05       Impact factor: 41.582

Review 9.  DNA hypermethylation in tumorigenesis: epigenetics joins genetics.

Authors:  S B Baylin; J G Herman
Journal:  Trends Genet       Date:  2000-04       Impact factor: 11.639

10.  Epstein-barr virus-positive gastric carcinoma demonstrates frequent aberrant methylation of multiple genes and constitutes CpG island methylator phenotype-positive gastric carcinoma.

Authors:  Gyeong Hoon Kang; Sun Lee; Woo Ho Kim; Hye Won Lee; Jin Cheon Kim; Mun-Gan Rhyu; Jae Y Ro
Journal:  Am J Pathol       Date:  2002-03       Impact factor: 4.307

View more
  17 in total

1.  Aberrant gene promoter methylation of p16, FHIT, CRBP1, WWOX, and DLC-1 in Epstein-Barr virus-associated gastric carcinomas.

Authors:  Dan He; Yi-wang Zhang; Na-na Zhang; Lu Zhou; Jian-ning Chen; Ye Jiang; Chun-kui Shao
Journal:  Med Oncol       Date:  2015-02-27       Impact factor: 3.064

2.  Reactive oxygen signaling and MAPK activation distinguish Epstein-Barr Virus (EBV)-positive versus EBV-negative Burkitt's lymphoma.

Authors:  Francesca Cerimele; Traci Battle; Rebecca Lynch; David A Frank; Emma Murad; Cynthia Cohen; Nada Macaron; John Sixbey; Kenneth Smith; Randolph S Watnick; Aristidis Eliopoulos; Bahig Shehata; Jack L Arbiser
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-20       Impact factor: 11.205

3.  Differential expression of apoptosis related proteins and nitric oxide synthases in Epstein Barr associated gastric carcinomas.

Authors:  Maria D Begnami; Andre L Montagnini; Andre L Vettore; Sueli Nonogaki; Mariana Brait; Alex Y Simoes-Sato; Andrea Q A Seixas; Fernando A Soares
Journal:  World J Gastroenterol       Date:  2006-08-21       Impact factor: 5.742

4.  Relationship between Epstein-Barr virus-encoded proteins with cell proliferation, apoptosis, and apoptosis-related proteins in gastric carcinoma.

Authors:  Yun Wang; Bing Luo; Li-Ping Yan; Bao-Hua Huang; Peng Zhao
Journal:  World J Gastroenterol       Date:  2005-06-07       Impact factor: 5.742

5.  EBV-infection in cardiac and non-cardiac gastric adenocarcinomas is associated with promoter methylation of p16, p14 and APC, but not hMLH1.

Authors:  Helene Geddert; Axel zur Hausen; Helmut E Gabbert; Mario Sarbia
Journal:  Cell Oncol (Dordr)       Date:  2011-05-03       Impact factor: 6.730

6.  Role of p53, apoptosis, and cell proliferation in early stage Epstein-Barr virus positive and negative gastric carcinomas.

Authors:  H H Ishii; G C Gobe; J Yoneyama; M Mukaide; Y Ebihara
Journal:  J Clin Pathol       Date:  2004-12       Impact factor: 3.411

7.  Epstein-Barr virus and gastric carcinoma--viral carcinogenesis through epigenetic mechanisms.

Authors:  Hiroshi Uozaki; Masashi Fukayama
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

8.  Molecule action mechanisms of NM-3 on human gastric cancer SGC-7901 cells in vivo or in vitro.

Authors:  Jin-Shui Zhu; Bo Shen; Jin-Lian Chen; Guo-Qiang Chen; Xiao-Hu Yu; Hua-Fang Yu; Zu-Ming Zhu
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

9.  Epstein-Barr virus induces an oxidative stress during the early stages of infection in B lymphocytes, epithelial, and lymphoblastoid cell lines.

Authors:  Saloua Lassoued; Randa Ben Ameur; Wajdi Ayadi; Bochra Gargouri; Riadh Ben Mansour; Hammadi Attia
Journal:  Mol Cell Biochem       Date:  2008-04-15       Impact factor: 3.396

Review 10.  Epstein-Barr virus: more than 50 years old and still providing surprises.

Authors:  Lawrence S Young; Lee Fah Yap; Paul G Murray
Journal:  Nat Rev Cancer       Date:  2016-09-30       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.